Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14837181 | 0.83 | LDHA (0.42) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL917909 | 0.76 | PARP1 (0.39) | AMY1A | |
| SCHEMBL14836947 | 0.75 | PARP1 (0.39) | KMT2ASMN1; SMN2 | |
| SCHEMBL14837159 | 0.74 | KMT2A (0.41) | KDM4EALDH1A1HSD17B10POLBKMT2A | |
| SCHEMBL14837487 | 0.74 | ACHE (0.40) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL14837106 | 0.73 | KMT2A (0.43) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL917974 | 0.73 | CYP2A6 (0.39) | — | |
| SCHEMBL27796221 | 0.73 | PARP1 (0.32) | ALDH1A1 | |
| SCHEMBL27796234 | 0.72 | ALDH1A1 (0.44) | KDM4EALDH1A1LMNAPOLBKMT2A | |
| SCHEMBL14837184 | 0.72 | LMNA (0.39) | KDM4EALDH1A1HSD17B10LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | claimed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | claimed |
| EP-1758864-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123687-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | WO | claimed |
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| CN-1968929-B | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments | SANOFI AVENTIS DEUTSCHLAND | 2010-09-08 | — | — | CN | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| EP-1758864-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123687-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885ALDH1A1 234/4885HSD17B10 1723/4885 |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885ALDH1A1 234/4885HSD17B10 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.